Treatment
Psilocybin clinical trials
We’re tracking 103 recruiting studies that include Psilocybin, each written for real people, not researchers, below.
Recruiting studies
- NCT06367738RecruitingPhase 1
Psilocybin and brain changes in healthy older adults
This study looks at how a single dose of psilocybin (the active ingredient in magic mushrooms) affects brain structure in healthy older adults. You'll receive the drug in a safe setting and have brain scans before and after to see if it promotes positive changes.
Berkeley, CaliforniaAges 60–85 - NCT06349083RecruitingPhase 2
Psilocybin-assisted treatment for alcohol use disorder
This study tests whether psilocybin, a psychedelic drug, combined with therapy can help people reduce or stop drinking. It aims to understand how psilocybin affects the brain and behavior in people with alcohol use disorder.
New York, New YorkAges 18–65 - NCT06355414RecruitingPhase 1
Psilocybin for chronic back pain and depression
This trial tests if psilocybin, a psychedelic drug, can help people with long-term low back pain who also have depression. If you qualify, you'll receive psilocybin in a controlled setting, and researchers will see how it affects your pain and mood.
Baltimore, MarylandAges 21–80 - NCT06233344RecruitingPhase 2
Mindfulness and psilocybin study for healthy adults
This study tests whether combining mindfulness training with a single dose of psilocybin (a psychedelic found in certain mushrooms) can help healthy adults. It aims to explore how these two approaches together might improve well-being.
Los Angeles, CaliforniaAges 25 years+ - NCT06247839RecruitingPhase 3
Psilocybin for depression: changing self-focus
This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.
Charlestown, MassachusettsAges 18–55 - NCT06160284RecruitingPhase 1
Psilocybin for brain healing in opioid recovery
This study tests whether psilocybin, a psychedelic substance, can help change brain connections in people recovering from opioid use disorder. It involves brain scans and careful medical monitoring to explore new treatment options.
New Haven, ConnecticutAges 25–55 - NCT06072898RecruitingPhase 2
Psilocybin brain imaging trial for depression
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
Toronto, OntarioAges 18–64 - NCT06067737RecruitingPhase 2
Psilocybin and buprenorphine for opioid use disorder
This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.
Baltimore, MarylandAges 21–70 - NCT04882839RecruitingPhase 2
Therapy with psilocybin for severe OCD symptoms
This Phase 2 study tests whether psilocybin-assisted psychotherapy can reduce symptoms in adults with severe, treatment-resistant OCD. It also focuses on safety and whether this approach is practical to run.
BeershebaAges 18–65 - NCT06001749RecruitingPhase 2
Psilocybin for cancer pain study
This trial tests whether psilocybin (a psychedelic drug) can help with severe cancer pain. You may qualify if your pain is high despite strong medications and you are willing to be monitored closely.
Boston, MassachusettsAges 18 years+ - NCT05403086RecruitingPhase 2
Psilocybin for distress in people with serious, life-limiting illness
This Phase 2 study tests whether psilocybin therapy can reduce deep distress (“demoralization”) in people receiving palliative (comfort-focused) care. It may help with mood and well-being, but you must meet safety and medication requirements to join.
Greenbrae, CaliforniaAges 18 years+ - NCT05866471RecruitingPhase 1
Testing nerve stimulation plus psilocybin for emotional well-being
This early safety study tests whether stimulating a nerve (taVNS) combined with psilocybin can change emotional well-being. It also checks safety issues like heart rhythms, lab results, and whether fMRI brain scans are possible.
Madison, WisconsinAges 18–70 - NCT05585229RecruitingPhase 2
Psilocybin therapy to help you taper opioid pain medicine
This Phase 2 study tests a structured, therapist-led treatment using standardized natural psilocybin to help people reduce or stop long-term opioid use for chronic (non-cancer) pain. It’s mainly for those who have tried tapering before but couldn’t, and who are motivated to try again.
Kelowna, British ColumbiaAges 19–75 - NCT05570708Enrolling by invitation
Therapist training trial on how experience shapes therapy
This study looks at how therapists’ personal experience affects their attitude and skills during substance-assisted therapy training. It’s mainly for therapists-in-training, and may help improve how future training and therapy are delivered safely.
BaselAges 27 years+ - NCT05452772RecruitingPhase 2
Psilocybin plus niacin to help quit smoking
This Phase 2 study tests whether a psilocybin “session” with niacin can help people quit smoking. It’s for adults who smoke daily and want to quit but have tried and struggled before.
Birmingham, AlabamaAges 21 years+ - NCT05398484RecruitingPhase 2/Phase 3
Psilocybin therapy for advanced cancer-related anxiety
This trial studies whether psilocybin (with support and therapy) can reduce anxiety in people with advanced cancer. It may help with distress and quality of life, while the study team monitors safety closely.
Aurora, ColoradoAges 21–100 - NCT05301608RecruitingPhase 1/Phase 2
Psilocybin study of brain activity and changing thoughts
This Phase 1/2 study tests psilocybin to see how it affects brain signals and the “content” of thoughts while you are monitored during the study. Because participants must be generally healthy and mentally stable, it may be an option if you meet those safety and medication rules and are comfortable having your brain activity measured.
Baltimore, MarylandAges 18–75 - NCT05265546RecruitingPhase 1
Psilocybin study of changes in how you see
This Phase 1 study tests whether psilocybin affects visual perception and how visual information is represented in the brain. It also studies safety and what brain/vision changes happen after the dose.
Berkeley, CaliforniaAges 21 years+ - NCT05068791RecruitingEarly Phase 1
Psilocybin-assisted treatment for long-term body pain
This early trial studies whether psilocybin, given in a supported setting, can reduce long-term widespread musculoskeletal pain (including fibromyalgia-like symptoms). You would be monitored closely and need someone to take you home after the medicine session.
Birmingham, AlabamaAges 25–65 - NCT04161066RecruitingPhase 1
Psilocybin plus buprenorphine to help opioid use disorder symptoms
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
Madison, WisconsinAges 21–65 - NCT04123314RecruitingEarly Phase 1
Psilocybin study for depression in mild memory or early Alzheimer’s
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
Baltimore, MarylandAges 18–85 - NCT07737990Enrolling by invitation
Psilocybin group therapy for treatment-resistant depression
This trial tests whether psilocybin-assisted group therapy can help people whose depression hasn't improved with other treatments. You must have already completed a prior psilocybin study to join this group.
Toronto, OntarioAges 18 years+ - NCT07570654RecruitingPhase 2/Phase 3
Testing COMP360 for post-traumatic stress disorder
This study tests whether COMP360, a new treatment, can help people with PTSD feel better and cope with their symptoms. The research team will measure how safe it is and how well it works over time.
Miami, FloridaAges 18 years+ - NCT03289949RecruitingPhase 1
Study brain effects of a serotonin system drug in adults
This Phase 1 study tests how a serotonin-related drug changes brain activity in healthy adults, using brain imaging (MRI) and other measures. Because it involves a drug that may affect the brain, eligibility is designed to keep the results safe and clear.
CopenhagenAges 18 years+
Common questions
- Are there clinical trials studying Psilocybin?
- Yes. Clin2 currently lists 103 recruiting studies that include Psilocybin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Psilocybin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Psilocybin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Psilocybin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.